Transcribed: Gleb Kuznetsov on breaking the in vivo bottleneck and building a true platform company скачать в хорошем качестве

Transcribed: Gleb Kuznetsov on breaking the in vivo bottleneck and building a true platform company

Gleb Kuznetsov left Google to chase a bigger problem in biology. What began as a butt-dial from a former classmate led him to George Church's lab, where he went from research engineer to Harvard PhD student to co-founding Manifold Bio — a company that's fundamentally changing how drug discovery works by screening over 500,000 antibody designs in a single animal study. In this episode of Transcribed, Gleb joins Benchling CEO Sajith Wickramasekara to talk about leaving tech for science, what makes the Church Lab a launchpad for biotech founders, and why domain expertise is the real moat in AI-driven drug discovery. 💡 Learn more about Manifold Bio: https://www.manifold.bio/ Chapters: 0:00 Intro 01:04 Disrupting R&D's biggest bottlenecks 05:27 Leaving Google for academia 17:33 The secret behind the Church Lab 26:44 The birth of Manifold 41:32 Betting the company on a pivot 48:38 Partnerships take time 52:22 What makes a true platform company 58:58 What actually attracts AI talent to biotech 1:02:39 The compounding value of open source 1:09:36 Approaching zero-shot clinical design 1:11:52 There's no shortcut to domain expertise 1:12:58 Lightning round